Picture of Veru logo

VERU Veru Share Price

0.000.00%
us flag iconLast trade - 00:00
Consumer DefensivesSpeculativeMid CapFalling Star

Momentum

Relative Strength (%)
1m-47.18%
3m-50.02%
6m-59.14%
1yr+8.91%
Volume Change (%)
10d/3m-46.06%
Price vs... (%)
52w High-76.95%
50d MA-40.83%
200d MA-48.96%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-87.89%
Return on Equity-71.87%
Operating Margin-211.47%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Sep 202330th Sep 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Veru EPS forecast chart

Profile Summary

Veru Inc. is an oncology biopharmaceutical company. The Company is focused on developing medicines for the management of breast and prostate cancers. The Company's FC2 segment consists of its commercial product, FC2. The Pharmaceuticals segment includes activities related to multiple drug products under clinical development and ENTADFI, a treatment for benign prostatic hyperplasia. It has a commercial Sexual Health Division, which includes two products, such as ENTADFI, a treatment for benign prostatic hyperplasia (BPH), and the FC2 Female Condom (Internal Condom) (FC2), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. Its breast cancer drug pipeline has four clinical development programs for two drugs, such as enobosarm, an oral selective androgen receptor targeting agonist, and sabizabulin, an oral cytoskeleton disruptor. Its prostate cancer drug pipeline includes sabizabulin, VERU-100 and zuclomiphene citrate.

Directors

Last Annual
September 30th, 2022
Last Interim
September 30th, 2022
Incorporated
February 4th, 1971
Public Since
July 19th, 1990
No. of Employees
233
Sector
Personal & Household Products & Services
Industry
Consumer Defensives
Exchange
us flag iconNASDAQ Capital Market
Shares in Issue
80,623,128

VERU Share Price Performance

Upcoming Events for VERU

Q1 2023 Veru Inc Earnings Release

Veru Inc Annual Shareholders Meeting

Q2 2023 Veru Inc Earnings Release

Similar to VERU

Picture of Beauty Health Co logo

Beauty Health Co

us flag iconNASDAQ Capital Market

Picture of Car House Holding Co logo

Car House Holding Co

us flag iconNASDAQ Capital Market

Picture of Color Star Technology Co logo

Color Star Technology Co

us flag iconNASDAQ Capital Market

FAQ

Or unlock with your email

Or unlock with your email